Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Bevacizumab
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 16 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Jun 2019.
- 16 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
- 02 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.